Thursday, August 25, 2016

Analyst highlights Novadaq, Cipher on BNN

Analyst highlights Novadaq, Cipher on BNN

July 7, 2014 by · Leave a Comment 

Tweet Douglas Loe, a health care and biotech analyst with Euro Pacific Canada, discussed the state of the sector today in an interview with BNN’s Pamela Richie. Mr. Loe’s buy recommendations include Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) and Cipher Pharmaceuticals (OTCBB:CPHMF; TSX:DND). The interview can be accessed here.

Larry Andrews steps down as Cipher Pharma head

Larry Andrews steps down as Cipher Pharma head

March 14, 2014 by · Leave a Comment 

Tweet Larry Andrews will be stepping down from his position as president and CEO of Cipher Pharmaceuticals (OTCBB:CPHMF; TSX:DND). To ensure a smooth transition of responsibilities, Mr. Andrews will remain with the company for a period of time while the board undertakes a search process. He will then continue working with Cipher in a consulting […]

Cipher readies regulatory filings for acne product

Cipher readies regulatory filings for acne product

October 26, 2011 by · Leave a Comment 

Tweet Cipher Pharmaceuticals (TSX:DND) is on track to file Health Canada and FDA submissions this quarter for its high-potential acne product, CIP-Isotretinoin, which is expected to trigger a $1 million milestone payment from its U.S. partner. The FDA review under PDUFA is expected to be six months. “With Lipofen generating steady revenue and our tramadol […]

Cipher signs up Canadian distributor for Tramadol

Cipher signs up Canadian distributor for Tramadol

September 26, 2011 by · Leave a Comment 

Tweet Cipher Pharmaceuticals (TSX:DND) has entered into a distribution and supply agreement with Medical Futures, a closely held Canadian pharmaceutical company, for the marketing of Durela in Canada. Durela is Cipher’s once-daily capsule formulation of tramadol, which has both immediate-release and extended-release components for the treatment of moderate-to-moderately severe chronic pain in adults. “This agreement, […]

Cipher’s tramadol cleared by Health Canada

Cipher’s tramadol cleared by Health Canada

August 31, 2011 by · Leave a Comment 

Tweet Cipher Pharmaceuticals (TSX:DND) has received Health Canada approval for its CIP-Tramadol ER, an extended-release treatment of moderate to moderately severe chronic pain in adults. “This represents the second regulatory approval for our extended-release tramadol and another important milestone for the company,” CEO Larry Andrews said in a statement. “We believe our product’s unique attributes, […]

Cipher completes CIP-Isotretinoin enrolment

Cipher completes CIP-Isotretinoin enrolment

October 29, 2010 by · Leave a Comment 

Tweet Cipher Pharmaceuticals (TSX:DND) has completed patient enrolment in a Phase 3 safety study of its CIP-Isotretinoin treatment of severe, nodular acne. A total of 931 patients were enrolled in the trial, of which 626 have completed treatment to date. Following an estimated six-month treatment period, the last subject enrolled should complete treatment in April, […]

Cipher readying tramadol launch in first quarter 2011

Cipher readying tramadol launch in first quarter 2011

July 28, 2010 by · Leave a Comment 

Tweet Cipher Pharmaceuticals (TSX: DND) is “working diligently” to finalize a marketing partnership and is finalizing commercial manufacturing requirements for its extended-release tramadol drug, which was cleared by the FDA in the second quarter, as it prepares for a commercial launch expected in the first quarter of 2011. The company also disclosed in its second […]

Cipher gets sales milestone for Lipofen

Cipher gets sales milestone for Lipofen

July 7, 2010 by · Leave a Comment 

Tweet Cipher Pharmaceuticals‘ (TSX:DND) Lipofen fenofibrate product reached a cumulative sales milestone, triggering a $1 million (U.S.) milestone payment from Kowa Pharmaceuticals America, Cipher’s U.S. marketing and distribution partner. The milestone payment will be reflected in Cipher’s revenue for the second quarter of fiscal 2010. “Kowa continues to do an excellent job with the promotion […]

Cipher plans to license-in new drug this year

Cipher plans to license-in new drug this year

January 5, 2010 by · 1 Comment 

Tweet For much of its six years as a separate company, Cipher Pharmaceuticals (TSX:DND) has been known for driving its three drugs toward the finish line.  That could change in 2010. “We ramped up our in-house resources last year to look at adding pipeline opportunities, and we’ve looked at over 100 to this stage,” CEO Larry […]

Email Newsletters with Constant Contact
Google+